Jeffrey W. Sherman

CIK: 0001230482

Transaction Breakdown

Open Market Buys (P)1 (16.7%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LRMR

Larimar Therapeutics, Inc.

Director

XERS

Xeris Biopharma Holdings, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

LRMR
Larimar Therapeutics, Inc.
May 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
55.2K shares-
LRMR
Larimar Therapeutics, Inc.
Feb 27, 2026
Purchase(P)
Direct
5K shares at avg. $5.00$25K
XERS
Xeris Biopharma Holdings, Inc.
Aug 28, 2025
Exercise(M)
Direct
47K shares at avg. $6.66$313K
XERS
Xeris Biopharma Holdings, Inc.
Aug 28, 2025
Sale(S)
Direct
42.2K shares at avg. $7.92$335K
XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2025
Award(A)
Direct
50K shares-
LRMR
Larimar Therapeutics, Inc.
May 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-

		Type	Shares	Price		Ownership
May 19, 2026	LRMR Larimar Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	55,150	-	-	Direct
Feb 27, 2026	LRMR Larimar Therapeutics, Inc.	Purchase(P)	5,000	$5.00	$25,000	Direct
Aug 28, 2025	XERS Xeris Biopharma Holdings, Inc.	Exercise(M)	47,040	$6.66	$313,286	Direct
Aug 28, 2025	XERS Xeris Biopharma Holdings, Inc.	Sale(S)	42,232	$7.92	$334,515	Direct
Jun 4, 2025	XERS Xeris Biopharma Holdings, Inc.	Award(A)	50,000	-	-	Direct
May 13, 2025	LRMR Larimar Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct

1-6 of 6 transactions

About SHERMAN JEFFREY W

SHERMAN JEFFREY W (SEC CIK 0001230482) files insider reports with the SEC as Director of Larimar Therapeutics, Inc. (LRMR) and Director of Xeris Biopharma Holdings, Inc. (XERS).

Signal8 holds 5 ownership filings by SHERMAN JEFFREY W, all Form 4s, filed between May 14, 2025 and May 20, 2026. Those filings report 6 transactions, from May 13, 2025 to May 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SHERMAN JEFFREY W's filings is in BALA CYNWYD, PA.

Recent filings by SHERMAN JEFFREY W

May 19, 2026: Grant or award of LRMR derivative securities (Form 4, code A).
Feb 27, 2026: Open-market purchase of LRMR shares (Form 4, code P).
Aug 28, 2025: Option exercise of XERS shares (Form 4, code M).
Aug 28, 2025: Open-market sale of XERS shares (Form 4, code S).
Jun 4, 2025: Grant or award of XERS shares (Form 4, code A).

Other insiders filing for Larimar Therapeutics, Inc. (LRMR)

Harlow John B. Jr., President and COO
Hamilton Thomas Edward, Director
Flynn James E, Director
LEFF JONATHAN S, Director
Truitt Joseph, Director
THOMAS FRANK E, Director

How to read Form 4 transaction codes